Abstract
BackgroundImmune checkpoint inhibitors (ICIs)-based treatments have been recommended as the first line for refractory recurrent and/or metastatic nasopharyngeal carcinoma (NPC) patients, yet responses vary, and predictive biomarkers are urgently needed....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have